A small biotech gem with lots of potential.
I really like the stocks. But I also like making money on stocks.

HCA Is Still Worth Holding Real Money Pro($)

Growing health care company has more room to run.

Gilead Set Up for a Breakout Real Money Pro($)

There is now a low-risk entry opportunity for GILD bulls.
For Bluebird Bio and Esperion, the charts tell the whole story.
A Fed-related dip may be your only hope to get in lower.
Amgen and Gilead shine in one of the market's best-performing sectors.
It shouldn't be possible, but it never seems too late to get in.

The Fibocall: Merck Real Money Pro($)

The shares are inside the bounce zone.

Small-Cap Focus: Navidea Real Money Pro($)

Aggressive investors should look at a small speculative position.

Columnist Conversations

Google rallied off its 2012 low making a series of higher highs and higher lows for two years. The pullback to...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.